SecBot SecBot
6-K ·Filed Jun 15, 2026

CXXIF

C21 Investments Inc.
BULLISH
Impact 7/10
Horizonmonths Processed5mo ago SEC0001062993-26-003202
Notable filing: 6-K
Actionable Insight ▲ Bullish

C21 shareholders should evaluate the implied value of the Vireo stock consideration relative to current CXXIF trading levels. Monitor the shareholder vote and regulatory approval timeline. The deal is expected to close in Q3 2026, after which CXXIF will be delisted.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.2490
T+0 close · Jun 15, 2026 · via day close
Latest settled
−4.02%
T+20 · $0.2390
Vs SPY
−3.88%
α at T+20
Next horizon
T+60
due 2mo ago
  1. T+0 · Jun 15 $0.2490entry
  2. T+1 · 5mo ago −3.69%α −3.10% · $0.2398
  3. T+5 · 5mo ago −1.20%α +1.41% · $0.2460
  4. T+20 · 4mo ago −4.02%α −3.88% · $0.2390
  5. T+60 · due 2mo ago Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

C21 Investments Inc. announced a definitive arrangement agreement to be acquired by Vireo Growth Inc. in an all-stock transaction. Each C21 share will be exchanged for 0.023052 Vireo shares, with the deal expected to close in Q3 2026, subject to shareholder and regulatory approvals. This represents a transformative event for C21 shareholders, who will receive equity in a larger multi-state operator.

Key Facts

  • C21 shareholders will receive 0.023052 Vireo shares per C21 share held.
  • Transaction unanimously approved by C21 Board (with interested directors abstaining) and recommended by Special Committee.
  • Needham & Company provided a fairness opinion to C21 Board.
  • Termination fee of US$3,000,000 payable by C21 to Vireo under certain circumstances.
  • C21 shares expected to be delisted from CSE and OTCQX upon closing.
  • Shareholder meeting expected in Q3 2026; deal subject to court and regulatory approvals.
  • Voting support agreements in place with certain C21 directors and officers.

Financial Impact

All-stock acquisition; exchange ratio of 0.023052 Vireo shares per C21 share. No cash consideration disclosed. Termination fee of US$3,000,000.

share priceownership structureliquidity

Risk Factors

  • Shareholder vote may not achieve required two-thirds majority.
  • Regulatory or court approvals could be delayed or denied.
  • Vireo's stock price could decline, reducing the value of consideration for C21 shareholders.
  • Termination fee and deal protection provisions may deter competing bids.

Market Snapshot

Exchange
OTC
Sector
Medicinal Chemicals & Botanical Products

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001062993-26-003202
Document: form6k.htm0001062993-26-003202
Document: 0001062993-26-003202-index-headers.html0001062993-26-003202
Document: 0001062993-26-003202-index.html0001062993-26-003202
Document: 0001062993-26-003202.txt0001062993-26-003202

Track record

4 reports on CXXIF

Performance horizon
Filters
  1. Aug 21, 202612w ago 6-K Bearish 5/10 Entry $0.2590 No price data
  2. Jun 15, 202622w ago 6-K Bullish 7/10 Viewing Entry $0.2490 to $0.2390 ▼ −4.02% −3.88% vs SPY
  3. Jun 12, 202622w ago 20-F Mixed 5/10 Entry $0.2700 to $0.2388 ▼ −11.56% −12.82% vs SPY
  4. Jun 12, 202622w ago 6-K Mixed 5/10 Entry $0.2700 to $0.2388 ▼ −11.56% −12.82% vs SPY
Showing 4 of 4

US Market Status

Market Closed · Opens in 5h 48m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 15, 2026